Clinical Trials Logo

Clinical Trial Summary

The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib(500mg/d)for the second - line treatment of esophageal cancer or esophageal and gastric


Clinical Trial Description

This study is a prospective,single-center,single arm,Ⅱ exploratory study.To explore the clinical study of the efficacy and safety of the treatment of vegfr-2 high expression by apatinib mesilate.The main research object for first-line treatment failure Ⅲ/Ⅳ integration of a period of esophageal or gastric esophagus cancer patients.The main purpose of the study was to evaluate apatinib for the median PFS of the esophageal and esophageal gastric junction carcinoma of the esophagus with high expression of VEGFR-2. The objective of secondary research is to evaluate the safety of apatinib for second-line treatment of esophageal and esophageal gastric junction cancer Objective Response Rate (CR + PR) and median OS and explore the relationship between VEGFR-2 high expression and apatinib efficacy and related prognostic factors. Thirty patients were enrolled in the study group. The group was expected to be enrolled in the group for 24 months, followed by 6 months of follow-up and 6 months of data statistics. The drug regimen was a single drug apatinib 500mg qd Po.Please refer to the CRF table for details. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03285906
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Pan Zhanyu, Master
Phone 86-13752570372
Email liyanwei127@hotmail.com
Status Recruiting
Phase Phase 2/Phase 3
Start date March 1, 2017
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT04648917 - GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC) Phase 3